Clinical trial
Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
NCT03928847 is registered in ClinicalTrials.gov with Hal Chapman as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
- Lead sponsor
- Hal Chapman
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 1, 2017
- Completion date
- May 31, 2019
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.